New drug combo aims to control advanced cancers
NCT ID NCT06332755
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called LB-LR1109 in people with advanced solid tumors like lung, kidney, head and neck, bladder, or skin cancer that has not responded to standard treatments. The study first gives the drug alone, then in combination with another cancer drug (atezolizumab) for lung cancer patients. The main goals are to find the safest dose and check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NEXT Oncology
RECRUITINGFairfax, Virginia, 22031, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of radiation and immunotherapy shrink head and neck tumors before surgery?
- Can an immunotherapy combo shrink head and neck tumors before surgery?
- Can two immune boosters beat advanced melanoma?
- Can a Direct-to-Tumor chemo blast halt advanced lung cancer?
- Smart patch and app aim to boost lung recovery after cancer surgery
- Can a new nucleotide analogue boost cancer treatment?